Brain tumor

NOXXON Reports H1 2021 Financial Results and Provides Business Update

Retrieved on: 
Friday, October 22, 2021
Pharmaceutical, Health, Oncology, MSD, Safety, Merck, Neoplasm, TME, General counsel, Cancer, Brain, Radiation, Terminology, NOX-A12, GBM, Communication, Clinical trial, R, GLORIA, Therapy, Immune system, D, Tumor microenvironment, Research, CFO, Group, Brain tumor, List of life sciences, Income, Senior, MGMT, Company, Supervisory board, Merck Sharp & Dohme Federal Credit Union, Pancreatic cancer, Biotechnology, Initial public offering, Industry, ESMO, PD-1, CEO, Immunotherapy, Population, Sale, Pembrolizumab, OPERA, Noxxon Pharma, Patient, Comparison, Genmab, Merck & Co., Glioblastoma, Standard of care, G&A, COVID, SAB, Journal, Fine chemical, Medical imaging, Pharmaceutical industry, Animal, NOXXON, the GLORIA Study, the OPTIMUS Study, NOXXON, THE GLORIA STUDY, THE OPTIMUS STUDY

For the reporting period, the Group NOXXON Pharma N.V. and NOXXON Pharma AG has not generated any revenues.

Key Points: 
  • For the reporting period, the Group NOXXON Pharma N.V. and NOXXON Pharma AG has not generated any revenues.
  • The R&D expenses increased by 421% in H1 2021 over the same period last year as NOXXON continued to make progress with the clinical stage assets.
  • NOXXON had a busy and productive H1 2021 period on the R&D front with significant progress made on its lead asset, NOX-A12.
  • In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements.

Outlook on the Brain Tumor Therapeutics Global Market to 2028 - by Type, Application, End-users, Countries and Companies - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 20, 2021
Health, Oncology, Research, Growth, Company, Therapy, Brain tumor, Automation, COVID, Industry, Medical imaging, Pharmaceutical industry

This report analyzes emerging market trends, market size outlook, potential opportunities, market share by Brain Tumor Therapeutics types, applications.

Key Points: 
  • This report analyzes emerging market trends, market size outlook, potential opportunities, market share by Brain Tumor Therapeutics types, applications.
  • Further, Brain Tumor Therapeutics market size is forecast by country and the study analyzes the key companies operating in the global Brain Tumor Therapeutics industry.
  • The global Brain Tumor Therapeutics market offers new growth opportunities for companies operating in the industry and new entrants.
  • On the other hand, Europe Brain Tumor Therapeutics market, US Brain Tumor Therapeutics market, Japan Brain Tumor Therapeutics market, and other developed markets require sound business strategy as these markets are largely user - driven and effective customer - focused strategies are required amidst increasing consumer expectations.

Oncology Pipeline Database 2021: Indication; Clinical Trial Stages; Drug Mechanism Classes; Competitive Landscape - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 14, 2021
Pharmaceutical, Health, Oncology, Cervical cancer, Cancer, Oncology Drug Advisory Committee, Database, Kidney cancer, Breast cancer, Hodgkin lymphoma, Colorectal cancer, Melanoma, Prostate cancer, Bladder cancer, Pancreatic cancer, Oncology, Multiple myeloma, Brain tumor, Dietary supplement, Medical imaging

Oncology Pipeline Highlights Database - 2021, provides the most up-to-date information on key pipeline products in the global Oncology Drug market.

Key Points: 
  • Oncology Pipeline Highlights Database - 2021, provides the most up-to-date information on key pipeline products in the global Oncology Drug market.
  • It covers emerging therapies for Oncology indications in active clinical development stages including early and late-stage clinical trials.
  • Key indications covered in this database include Esophageal Cancer Stomach Cancer, Colon Cancer, Pancreatic Cancer, Malignant Melanoma, Breast Cancer, Cervical Cancer, Ovary Cancer, Prostate Cancer, Renal Cancer, Bladder Cancer, Brain Cancer, Hodgkin's disease, Acute Myeloid Leukemia and Multiple Myeloma.
  • The database provides Oncology pipeline products by clinical trial stages including both early and late-stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Vionic Partners with St. Jude Children's Research Hospital and PNOC Foundation for the 2nd Year To Raise Awareness and Funds for Childhood Cancer

Retrieved on: 
Wednesday, September 1, 2021
People, Cancer, TikTok, American Cancer Society, St. Jude's, O, The Oprah Magazine, Twitter, Instagram, PNOC, Childhood cancer, Diagnosis, Ependymoma, Family, Survival, Social media, NCI-designated Cancer Center, Research, Nausea, St. Jude Children's Research Hospital, Travel, Comfort, Man, Awareness, National Cancer Institute, Child, National Cancer Center, Brain, ST, Survival rate, Brain tumor, Headache, SAN, Famous Footwear, Organization, Hospital, Housing, Women's health, Today (American TV program), Woman, Men's Health, CLIC Sargent, Birth control, Medical imaging, Fashion

SAN RAFAEL, Calif., Sept. 1, 2021 /PRNewswire/ --For the second year, Vionic has partnered with St. Jude Research Hospital and the PNOC Foundation to raise awareness and fund critical research for pediatric cancers during Childhood Cancer Awareness Month.

Key Points: 
  • SAN RAFAEL, Calif., Sept. 1, 2021 /PRNewswire/ --For the second year, Vionic has partnered with St. Jude Research Hospital and the PNOC Foundation to raise awareness and fund critical research for pediatric cancers during Childhood Cancer Awareness Month.
  • A diagnosis of childhood cancer is devastating for all members of a family, and personal for Vionic.
  • As one of the nearly two dozen corporate partners supporting St. Jude during Childhood Cancer Month, Vionic is proud to sponsor St. Jude's Childhood Cancer Awareness Month.
  • St. Jude Children's Research Hospital is leading the way the world understands, treats and defeats childhood cancer and other life-threatening diseases.

NaviFUS begins FUS combined with radiotherapy clinical trial for the treatment of terminal primary brain tumors

Retrieved on: 
Wednesday, August 4, 2021
Drugs, Health, Clinical medicine, Orphan drugs, Medical physics, Bevacizumab, Brain tumor, Radiation therapy, Breast cancer

TAIPEI, Aug. 4, 2021 /PRNewswire/ -- NaviFUS' focused ultrasound (FUS) therapy system (NaviFUS®) was recently approved for use in a new clinical trial by the Taiwan Food and Drug Administration (TFDA). It will be initiated shortly at Linkou Chang Gung Memorial Hospital. The trial will investigate the "synergy" that FUS-mediated opening of the blood-brain barrier (BBB) has on improving the therapeutic effect of radiotherapy treatment in patients with end-stage primary brain tumors. Despite suffering from repeating surgeries, radiotherapy, and chemotherapy, most of these patients will eventually face tumor recurrence. Currently, while there may not be any effective treatments guaranteed to prolong survival, NaviFUS hopes that this upcoming clinical trial can result in a new, low-risk, and "Patient Friendly" option for patients who have already exhausted first and second-line treatments or failed radiotherapy treatment previously. If this combined treatment can safely enhance the effect of radiotherapy, NaviFUS' believes this treatment can also be extended to metastatic brain tumors from lung cancer, breast cancer, etc. The market potential for this treatment is expected to be more than $2 billion US dollars.

Key Points: 
  • TAIPEI, Aug. 4, 2021 /PRNewswire/ -- NaviFUS' focused ultrasound (FUS) therapy system (NaviFUS) was recently approved for use in a new clinical trial by the Taiwan Food and Drug Administration (TFDA).
  • The trial will investigate the "synergy" that FUS-mediated opening of the blood-brain barrier (BBB) has on improving the therapeutic effect of radiotherapy treatment in patients with end-stage primary brain tumors.
  • If this combined treatment can safely enhance the effect of radiotherapy, NaviFUS' believes this treatment can also be extended to metastatic brain tumors from lung cancer, breast cancer, etc.
  • At the same time, NaviFUS is conducting a FUS-mediated BBB opening combined with bevacizumab (Avastin) clinical trial at Linkou Chang Gung Memorial Hospital.

NaviFUS begins FUS combined with radiotherapy clinical trial for the treatment of terminal primary brain tumors

Retrieved on: 
Wednesday, August 4, 2021
Clinical medicine, Medicine, Health, Orphan drugs, Medical physics, Brain tumor, Oncology, Bevacizumab, Radiation therapy, Breast cancer, Metástasis, Cancer

The trial will investigate the "synergy" that FUS-mediated opening of the blood-brain barrier (BBB) has on improving the therapeutic effect of radiotherapy treatment in patients with end-stage primary brain tumors.

Key Points: 
  • The trial will investigate the "synergy" that FUS-mediated opening of the blood-brain barrier (BBB) has on improving the therapeutic effect of radiotherapy treatment in patients with end-stage primary brain tumors.
  • If this combined treatment can safely enhance the effect of radiotherapy, NaviFUS' believes this treatment can also be extended to metastatic brain tumors from lung cancer, breast cancer, etc.
  • At the same time, NaviFUS is conducting a FUS-mediated BBB opening combined with bevacizumab (Avastin) clinical trial at Linkou Chang Gung Memorial Hospital.
  • "If these two non-invasive FUS treatments for brain tumors can be successfully developed, they can offer non-invasive treatment options with improved efficacy and minimal side effects."

Streamlining Brain Tumor Surgery Care During the Pandemic

Retrieved on: 
Monday, August 2, 2021
Medical specialties, Clinical medicine, Medicine, Neurosurgical procedures, Intensive care medicine, Intensive care unit, Craniotomy, Brain tumor

As U.S. health care eventually emerges from the pandemic, many aspects of surgical care, including how patients are prepared for surgery and where and how they recover will be forever altered.

Key Points: 
  • As U.S. health care eventually emerges from the pandemic, many aspects of surgical care, including how patients are prepared for surgery and where and how they recover will be forever altered.
  • The pandemic's strain on hospital ICUs and other facilities forced the PNI and Saint John's teams to reconsider some basic assumptions about brain tumor care and rapidly implement protocol enhancements that already had been in use on a more limited basis.
  • "Brain tumor surgery by craniotomy or endonasal removal is resource intensive and historically has required multi-day hospital admissions, often including recovery in the ICU," Dr. Kelly added.
  • There were no differences pre-pandemic versus pandemic in tumor removal rates, complications, readmissions or reoperations.

Global Cancer Technology Licenses Biomarker Technology from Baylor Scott & White Research Institute to Support Research Efforts Towards Treatment for Glioblastoma

Retrieved on: 
Friday, July 30, 2021
Clinical medicine, Medicine, Cancer, Oncology, Glioblastoma, Brain tumor, Biomarker

SAN DIEGO, July 30, 2021 /PRNewswire/ -- Global Cancer Technology today announced that the company has licensed biomarker technology from Baylor Scott & White Research Institute (BSWRI) under an exclusive option to support GCT's research efforts towards a treatment for glioblastoma.

Key Points: 
  • SAN DIEGO, July 30, 2021 /PRNewswire/ -- Global Cancer Technology today announced that the company has licensed biomarker technology from Baylor Scott & White Research Institute (BSWRI) under an exclusive option to support GCT's research efforts towards a treatment for glioblastoma.
  • GCT is currently executing on promising pre-clinical studies that could provide a treatment for the aggressive brain cancer using novel PI3K inhibitors .
  • "Baylor Scott & White Research Institute always delivers on its mission to promote the health and wellbeing of individuals, families, and communities.
  • I am happy that Global Cancer Technology licenses biomarker technology from BSWRI to support innovative research efforts towards diagnosis and treatment for glioblastoma," said Dr. Erxi Wu, Director of Neuro-Oncology Research Center, Baylor Scott & White Research Institute.

Basilea announces U.S. FDA Orphan Drug Designation granted to lisavanbulin for the treatment of malignant glioma

Retrieved on: 
Thursday, July 29, 2021
Cancer, Health, Brain tumor, Oncology, Basilea Pharmaceutica, Glioblastoma, Glioma, Orphan drug, Paclitaxel trevatide, Pelareorep

Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Basileas tumor checkpoint controller, lisavanbulin, for the treatment of malignant glioma (brain cancer).

Key Points: 
  • Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Basileas tumor checkpoint controller, lisavanbulin, for the treatment of malignant glioma (brain cancer).
  • Dr. Marc Engelhardt, Chief Medical Officer, commented: The Orphan Drug Designation of lisavanbulin by the U.S. FDA is an important milestone for the development of lisavanbulin.
  • Glioblastoma is associated with a poor prognosis and there are only very limited therapeutic options available.
  • Lisavanbulin, as a targeted treatment, could be a useful new approach to expand the treatment options for patients with this devastating disease.

Immunomic’s Academic Collaborator Dr. John Sampson Recognized as “World Expert” in Glioblastoma as Part of Glioblastoma Awareness Day

Retrieved on: 
Wednesday, July 21, 2021
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Mental health, Other Science, Research, Hospitals, Surgery, Science, Cancer, Health, Neoplasms, Oncology, Brain tumor, Glioblastoma, Blastoma

The publication recognized the top 0.1% of scholars writing about glioblastoma over the past ten years, a level they label as "World Expert.

Key Points: 
  • The publication recognized the top 0.1% of scholars writing about glioblastoma over the past ten years, a level they label as "World Expert.
  • Dr. Sampsons recognition as a World Expert in glioblastoma is part of Glioblastoma Awareness Day, which is being celebrated today, Wednesday, July 21, 2021.
  • This recognition is especially important today, on Glioblastoma Awareness Day, where we honor the patients, families, and care givers who have faced this complex and deadly type of brain cancer.
  • We look forward to continuing to collaborate with Dr. Sampson to advance our glioblastoma immunotherapy program, ITI-1000, through Phase 2 and toward patients in need.